Communiqués Intervacc AB

Actions

IVACC

SE0009607252

Recherche biotechnologique et médicale

PEA

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
1,270 ^SEK	-1,24 %		-.--%	+37,45 %

30/07	Intervacc dépose une demande de variation de type II auprès de l'EMA pour porter à 12 mois la durée d'immunité du Strangvac	CI
30/07	Intervacc sollicite l'approbation de l'UE pour prolonger la durée d'immunité de son vaccin équin	MT

Communiqués

30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
29/07	Intervacc: New Zealand order validates Strangvac’s position	AQ
29/07	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
04/06	Redeye initiates coverage of Intervacc	AQ
22/05	Intervacc: Positive results	AQ
22/05	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials	AQ
15/05	Intervacc: US progress, while European sales still soft – Q1 review	AQ
15/05	Emil Billbäck appointed new Chair of the Board of Intervacc	AQ
13/05	Report from Annual General Meeting in Intervacc	AQ
12/05	Intervacc strengthens management team for future growth	AQ
04/05	International Awareness Initiative Against Strangles	AQ
23/04	Intervacc brings together leading US and European experts to jointly tackle strangles	AQ
16/04	Unprecedented decision opens the way for the launch of Strangvac in Iceland	AQ
14/04	Intervacc publishes the 2025 Annual Report	AQ
10/04	Notice of Annual General Meeting in Intervacc AB (publ)	AQ
20/03	Intervacc: Highly promising data presented	AQ
19/03	Intervacc announces breakthrough protection against Streptococcus suis infection in piglets	AQ
09/03	Intervacc presents to the capital market on three occasions in March	AQ
18/02	Intervacc: Growth story remains despite weak quarter – Q4 review	AQ
17/02	Year-end report January - December 2025	AQ
06/02	Intervacc: New CEO announced	AQ
05/02	Intervacc announces change of CEO	AQ
16/12	Intervacc: Advancing the US approval process	AQ
16/12	Clinical studies with Strangvac have begun in the U.S. market	AQ
20/11	Intervacc: Solid quarter with strong sales growth – Q3 review	AQ